The Role of Thyroglobulin in Thyroid Hormone Synthesis
Project Number5K01DK125448-02
Former Number1K01DK125448-01
Contact PI/Project LeaderCITTERIO, CINTIA E.
Awardee OrganizationUNIVERSITY OF MICHIGAN AT ANN ARBOR
Description
Abstract Text
PROJECT SUMMARY/ ABSTRACT
Thyroid hormone (TH) deficiency impacts vertebrate physiology in a myriad of ways. The pediatric
consequences of congenital hypothyroidism (the most common congenital endocrinopathy worldwide) include
defective growth and hearing, and an inability to achieve maximal potential intelligence. In adults,
hypothyroidism leads to hyperlipidemia, altered thermogenesis, and weight gain promoting obesity. Throughout
the entire vertebrate subphylum, THs are synthesized within the precursor protein thyroglobulin (Tg), encoded
by the single TG gene, under the regulation of thyroid-stimulating hormone (TSH). Thyroxine (T4) derives
primarily from a unique, evolutionarily conserved site at the N-terminus of Tg (on position Tyr-5), whereas the
primary formation site for triiodothyronine (T3) derives from the opposite end of the Tg protein. Iodination of Tg
is the sole source of T4 in the body, but only a partial contributor to circulating T3 (the remaining T3 is converted
by deiodinating T4 in various organs). Treatment of hypothyroidism with T4 leaves many patients with persistent
hypothyroid symptoms, whereas direct treatment exclusively with T3 results in dramatic up-down swings in
blood levels of T3. I have been interested to know, what would be the consequences if the thyroid gland itself,
regulated moment-to-moment by TSH, could selectively produce all of the body’s T3? Under physiological
regulation by TSH, the carboxyl-terminal ChEL domain of Tg — by providing essentially exclusively T3
to the body — either will or will not be sufficient to sustain all critical developmental and metabolic
functions supported by TH. To test this I propose to use CRISPR/Cas9-mutagenesis to develop the first two
genetically-edited mouse models with homozygous TG knock-in mutants encoding either: a) a Tg-Y5F
substitution (eliminating the primary T4-forming site of Tg) or b) encoding only the secretory ChEL domain that
preserves the primary T3-forming site of Tg — in both cases leaving the primary T3-forming site of Tg intact in a
thyroid gland physiologically regulated by TSH. With these novel animals in hand, I will study development,
growth, behavior, hearing, body composition and weight, and thermoregulation. I will seek rigorous validation
of in vivo hormonogesis studies with parallel cell culture experiments to express the same Tg variants, and
characterize quantitatively their deficiency of T4 production but competence for T3 production, using Tg
iodination in vitro, followed by nano-liquid chromatography tandem-mass spectrometry. The plan outlined in
this 5-year K01 Award will permit me to develop additional expertise in whole animal thyroid pathophysiology
as well as cutting edge biochemical skills needed for my future independent scientific career. Furthermore, this
proposal is of significant clinical relevance to understand if there is any special role of T4 from
neonates to adults, while providing deep insight into the evolutionary origins of TH synthesis in
vertebrates, and opening new possibilities for future refinement in the management of human
hypothyroidism.
Public Health Relevance Statement
PROJECT NARRATIVE
Thyroid hormones, known as T4 (thyroxine) and T3 (triiodothyronine), are synthesized in the thyroid gland on
specific sites within the hormone precursor protein thyroglobulin. In this project, I will create mice with loss of
T4 formation while preserving T3 formation in thyroglobulin which will, for the first time, establish the extent to
which T4 is required for normal development, growth, behavior, hearing, body weight and composition, and
thermoregulation. My studies will aid in our understanding of the defects and treatment of hypothyroidism,
which affects 10% of the world’s population and constitutes the most common congenital endocrinopathy in
humans.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
847
DUNS Number
073133571
UEI
GNJ7BBP73WE9
Project Start Date
19-January-2022
Project End Date
31-July-2023
Budget Start Date
01-December-2022
Budget End Date
31-July-2023
Project Funding Information for 2023
Total Funding
$77,077
Direct Costs
$71,368
Indirect Costs
$5,709
Year
Funding IC
FY Total Cost by IC
2023
National Institute of Diabetes and Digestive and Kidney Diseases
$77,077
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5K01DK125448-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5K01DK125448-02
Patents
No Patents information available for 5K01DK125448-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5K01DK125448-02
Clinical Studies
No Clinical Studies information available for 5K01DK125448-02
News and More
Related News Releases
No news release information available for 5K01DK125448-02
History
No Historical information available for 5K01DK125448-02
Similar Projects
No Similar Projects information available for 5K01DK125448-02